Scarica l'app Stockscreener
3.45
4.43%
-0.16
Dopo l'orario di chiusura:
3.45
Precedente Chiudi:
$3.61
Aprire:
$3.62
Volume 24 ore:
313.16K
Relative Volume:
0.75
Capitalizzazione di mercato:
$269.54M
Reddito:
$351.37M
Utile/perdita netta:
$-174.01M
Rapporto P/E:
-1.6667
EPS:
-2.07
Flusso di cassa netto:
$-126.94M
1 W Prestazione:
-0.86%
1M Prestazione:
+9.87%
6M Prestazione:
-8.24%
1 anno Prestazione:
+3.29%
Intervallo 1D:
$3.43
$3.67
Intervallo di 1 settimana:
$3.285
$3.67
Portata 52W:
$2.455
$4.02
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Nome
Atea Pharmaceuticals Inc
Settore
Industria
Telefono
857-204-8109
Indirizzo
225 FRANKLIN STREET, BOSTON
Confronta AVIR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
3.45 | 282.04M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-13 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-01-06 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-10-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | Iniziato | Evercore ISI | Outperform |
| 2020-11-24 | Iniziato | JP Morgan | Overweight |
| 2020-11-24 | Iniziato | Morgan Stanley | Overweight |
| 2020-11-24 | Iniziato | William Blair | Outperform |
Mostra tutto
Atea Pharmaceuticals Inc Borsa (AVIR) Ultime notizie
Atea Pharmaceuticals to highlight strategic priorities for FY26 - Yahoo Finance
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Why Atea Pharmaceuticals Inc. stock is popular among millennials2025 Trading Volume Trends & Community Consensus Trade Alerts - ulpravda.ru
Will Atea Pharmaceuticals Inc. stock attract more institutional investorsProduct Launch & Entry Point Confirmation Signals - ulpravda.ru
Atea Pharmaceuticals Highlights 2026 Strategic Priorities - TradingView — Track All Markets
Atea Pharmaceuticals Advances Phase 3 Trials for HCV Treatment Regimen, Anticipates Significant Milestones in 2026 - Quiver Quantitative
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Is Atea Pharmaceuticals Inc. stock supported by strong cash flows2026 world cup usa national team qualification star players pressing system winner prediction breakdown - ulpravda.ru
Critical Survey: Atea Pharmaceuticals (NASDAQ:AVIR) vs. Regeneron Pharmaceuticals (NASDAQ:REGN) - Defense World
What analysts say about Atea Pharmaceuticals Inc stockTrading Volume Trends & Build a Smarter Portfolio Right Now - earlytimes.in
What drives Atea Pharmaceuticals Inc stock priceWeekly Market Snapshot & Access Free Risk Analysis Before You Invest - earlytimes.in
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 1.4%Here's What Happened - MarketBeat
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 1.4% – Here’s What Happened - Defense World
Rapt Therapeutics (NASDAQ:RAPT) & Atea Pharmaceuticals (NASDAQ:AVIR) Head-To-Head Contrast - Defense World
Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026 - Seeking Alpha
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus - Sahm
Is Atea Pharma Moving BEYOND The Virus And FORWARD To Breakthroughs? - RTTNews
Atea Pharmaceuticals Completes Enrollment in North American Phase 3 Trial of Hepatitis C Treatment - marketscreener.com
Atea Pharmaceuticals Completes Enrollment in C-BEYOND Phase 3 Trial for HCV Treatment, Anticipates Topline Results in Mid-2026 - Quiver Quantitative
Atea Pharmaceuticals Completes Patient Enrollment In North American Phase 3 Trial Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus - TradingView — Track All Markets
Atea Pharmaceuticals Completes Patient Enrollment in North - GlobeNewswire
Published on: 2025-12-21 17:47:39 - Улправда
Why analysts upgrade Atea Pharmaceuticals Inc. stockEarnings Overview Report & Stepwise Swing Trade Plans - Улправда
Is Atea Pharmaceuticals Inc. stock attractive for ETFsJuly 2025 Macro Moves & Safe Entry Trade Reports - Улправда
What is the fair value of Atea Pharmaceuticals Inc. stock nowTreasury Yields & Reliable Trade Execution Plans - Улправда
What technical charts say about Atea Pharmaceuticals Inc. stockJuly 2025 Breakouts & Safe Capital Growth Plans - Улправда
Aug Catalysts: What is the fair value of Atea Pharmaceuticals Inc. stock nowJuly 2025 Big Picture & Real-Time Stock Entry Alerts - Улправда
How rising interest rates impact Atea Pharmaceuticals Inc. stockEntry Point & Long Hold Capital Preservation Plans - DonanımHaber
Will Atea Pharmaceuticals Inc. stock maintain growth storyTrade Performance Summary & Free Real-Time Volume Trigger Notifications - DonanımHaber
Will Atea Pharmaceuticals Inc. stock deliver strong dividend growthQuarterly Earnings Report & Safe Entry Point Identification - DonanımHaber
Chart Watch: Is Atea Pharmaceuticals Inc. stock supported by strong cash flowsJuly 2025 PreEarnings & Weekly Stock Breakout Alerts - Улправда
Nano Dimension And 2 Other Penny Stocks With Promising Potential - simplywall.st
Atea Pharmaceuticals Earnings Notes - Trefis
Atea Pharmaceuticals (AVIR) Stock Analysis Report | Financials & Insights - Benzinga
Atea Pharmaceuticals (NASDAQ:AVIR) Trading Down 1.9%Should You Sell? - MarketBeat
We're Keeping An Eye On Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Rate - Yahoo Finance
How Atea Pharmaceuticals Inc. stock trades during market volatilityTrade Risk Assessment & Community Verified Trade Signals - Newser
Is Atea Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Macro Moves & Daily Growth Stock Tips - Newser
How Atea Pharmaceuticals Inc. stock valuations compare to rivalsTake Profit & Fast Entry High Yield Tips - Newser
How Atea Pharmaceuticals Inc. stock performs after earningsJuly 2025 Action & AI Enhanced Trading Signals - Newser
ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman - Stock Titan
Atea Pharmaceuticals director Franklin Berger acquires $81,498 in stock - MSN
Will Atea Pharmaceuticals Inc. stock beat EPS estimatesTrade Risk Report & Expert Approved Momentum Trade Ideas - newser.com
Is Atea Pharmaceuticals Inc. stock reversal real or fake2025 Winners & Losers & Technical Pattern Based Buy Signals - newser.com
Will Atea Pharmaceuticals Inc. stock outperform growth indexesJuly 2025 Action & Momentum Based Trading Ideas - newser.com
How strong is Atea Pharmaceuticals Inc. stock revenue growth2025 Historical Comparison & Growth Focused Investment Plans - newser.com
Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... By GuruFocus - Investing.com Canada
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference - Yahoo Finance
Atea Pharma (NASDAQ: AVIR) hosts Evercore fireside chat Dec. 3 at 10:00 a.m. ET - Stock Titan
Atea Pharmaceuticals Inc Azioni (AVIR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Atea Pharmaceuticals Inc Azioni (AVIR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
506,497 |
| Duncan Barbara Gayle | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Polsky Bruce | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
95,206 |
| Adams Jerome M. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Lucidi Bruno | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
112,750 |
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):